<!DOCTYPE html>

<html lang="en">
<head>
<meta charset="utf-8"/>
<meta content="width=device-width, initial-scale=1.0" name="viewport"/>
<title>BPaL Regimen: A Revolution in TB Treatment</title>
<style>
        * {
            margin: 0;
            padding: 0;
            box-sizing: border-box;
        }

        body {
            font-family: 'Georgia', serif;
            background-color: #fefefe;
            color: #333;
            line-height: 1.8;
            padding: 0 7px;
        }

        .container {
            max-width: 1200px;
            margin: 40px auto;
            padding: 20px;
            background-color: #ffffff;
            border-radius: 10px;
            box-shadow: 0 4px 20px rgba(0, 0, 0, 0.1);
        }

        h1, h2 {
            font-family: 'Merriweather', serif;
            color: #2c3e50;
            margin-bottom: 15px;
        }

        h1 {
            font-size: 2.2em;
            text-align: center;
            margin-bottom: 25px;
        }

        h2 {
            font-size: 1.5em;
            border-left: 4px solid #3498db;
            padding-left: 10px;
            margin-top: 30px;
        }

        p {
            margin-bottom: 1.5em;
        }

        .footer {
            margin-top: 30px;
            padding: 15px;
            background-color: #f9f9f9;
            border-top: 1px solid #ddd;
            text-align: center;
            border-radius: 0 0 10px 10px;
        }

        .tags {
            display: flex;
            flex-wrap: wrap;
            justify-content: center;
            gap: 10px;
            margin-top: 10px;
        }

        .tag {
            background-color: #e0f7fa;
            color: #00796b;
            padding: 5px 10px;
            font-size: 0.9em;
            border-radius: 20px;
            border: 1px solid #b2ebf2;
        }
    </style>
</head>
<body>
<div class="container">
<h1>BPaL Regimen: A Revolution in TB Treatment</h1>
<img alt="BPaL Regimen in TB Treatment" src="https://tbksp.who.int/sites/default/files/inline-images/tab-4-1_3.gif"/>
<p>The introduction of the BPaL regimen (bedaquiline, pretomanid, linezolid) is transforming TB treatment, offering reduced duration and fewer pills with lower toxicity.</p>
<h2>Advantages of the BPaL Regimen</h2>
<p>The regimen reduces treatment duration to six months, improves adherence, and provides a low-pill burden. It offers enhanced tolerance and reduced side effects compared to traditional regimens.</p>
<h2>Challenges and Considerations</h2>
<p>Adherence monitoring is crucial as resistance to bedaquiline has been observed. Drug-susceptibility testing and early diagnostics are needed to ensure regimen suitability. Linezolid may cause sensory neuropathy, which requires vigilance.</p>
<h2>Health System Preparedness</h2>
<p>Training of physicians and public-private partnerships are essential to ensure access and affordability, while addressing the high costs of the shorter regimen.</p>
<h2>Addressing Structural Barriers</h2>
<p>TB patients face stigma, and economic support is needed to overcome barriers. Addressing social determinants like poverty and overcrowding is essential for eradication.</p>
<h2>Way Forward</h2>
<p>A person-centred approach, along with community education and systemic transformation, is necessary to improve treatment adherence and reduce stigma.</p>
<div class="footer">
<h4>Tags</h4>
<div class="tags">
<span class="tag">BPaL-regimen</span>
<span class="tag">bedaquiline</span>
<span class="tag">pretomanid</span>
<span class="tag">linezolid</span>
<span class="tag">drug-resistant-TB</span>
<span class="tag">MDR-TB</span>
<span class="tag">TB-treatment</span>
<span class="tag">treatment-duration</span>
<span class="tag">adherence</span>
<span class="tag">low-pill-burden</span>
<span class="tag">toxicity</span>
<span class="tag">health-systems</span>
<span class="tag">drug-susceptibility-testing</span>
<span class="tag">social-determinants</span>
<span class="tag">stigma</span>
<span class="tag">healthcare-partnerships</span>
</div>
</div>
</div>
</body>
</html>
